MCID: INT253
MIFTS: 47

Intestinal Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Intestinal Benign Neoplasm

MalaCards integrated aliases for Intestinal Benign Neoplasm:

Name: Intestinal Benign Neoplasm 11 14
Intestinal Neoplasms 43 71
Neoplasm of Intestinal Tract 11
Intestinal Tumors 11
Intestine Growth 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4610
MeSH 43 D007414
NCIt 49 C3141
SNOMED-CT 68 126769007
UMLS 71 C0021841

Summaries for Intestinal Benign Neoplasm

Disease Ontology: 11 A gastrointestinal system benign neoplasm that is located in the intestine.

MalaCards based summary: Intestinal Benign Neoplasm, also known as intestinal neoplasms, is related to colonic benign neoplasm and colorectal adenoma, and has symptoms including constipation and diarrhea. An important gene associated with Intestinal Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Bisacodyl and Lutetium Lu 177 dotatate have been mentioned in the context of this disorder. Affiliated tissues include intestine, small intestine and colon, and related phenotype is neoplasm.

Related Diseases for Intestinal Benign Neoplasm

Diseases related to Intestinal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 472)
# Related Disease Score Top Affiliating Genes
1 colonic benign neoplasm 31.8 TP53 MUTYH MLH1 MIR21 MIR18A MIR15A
2 colorectal adenoma 31.5 TP53 MUTYH MLH1 MIR532 MIR31 MIR21
3 gastric cancer 31.5 TP53 MUTYH MLH1 MIR21 MIR20A MIR192
4 adenoma 31.1 TP53 MUTYH MLH1 KRAS HRAS CTNNB1
5 adenocarcinoma 31.1 TP53 MLH1 KRAS HRAS CTNNB1 APC
6 familial adenomatous polyposis 31.0 TP53 MUTYH MLH1 KRAS HRAS CTNNB1
7 small intestine adenocarcinoma 30.7 TP53 MLH1 KRAS HRAS CTNNB1
8 endometriosis 30.5 TP53 MIR20A MIR17 MIR143 MIR142
9 gastrointestinal stromal tumor 30.5 TP53 KRAS HRAS H2AC18 CTNNB1
10 neurofibromatosis 30.4 TP53 MLH1 KRAS HRAS
11 colon adenocarcinoma 30.3 TP53 MLH1 KRAS HRAS CTNNB1 APC
12 small intestine cancer 30.3 TP53 MUTYH MLH1 KRAS HRAS CTNNB1
13 desmoid tumor 30.3 TP53 MUTYH CTNNB1 APC
14 peutz-jeghers syndrome 30.2 TP53 CTNNB1 APC
15 crohn's disease 30.2 MIR31 MIR21 MIR192 MIR142 H2AC18 CCR6
16 neurofibromatosis, type i 30.2 TP53 MLH1 KRAS HRAS
17 bap1 tumor predisposition syndrome 30.1 TP53 MUTYH MLH1 APC
18 rasopathy 30.1 TP53 KRAS HRAS CTNNB1
19 gastric adenocarcinoma 30.1 TP53 MLH1 KRAS HRAS CTNNB1 APC
20 myelodysplastic syndrome 30.0 TP53 MIR17 MIR142 KRAS HRAS H2AC18
21 rectal benign neoplasm 30.0 TP53 MLH1 MIR31 MIR20A MIR17 MIR143
22 bladder cancer 29.9 TP53 MLH1 MIR31 MIR21 MIR17 MIR143
23 endometrial cancer 29.9 TP53 MUTYH MLH1 MIR21 KRAS HRAS
24 colorectal cancer 29.8 TP53 MUTYH MLH1 MIR532 MIR31 MIR21
25 body mass index quantitative trait locus 11 29.7 TP53 MIR532 MIR21 MIR20A MIR192 MIR18A
26 lynch syndrome 29.7 TP53 MUTYH MLH1 MIR532 MIR31 MIR18A
27 intestinal disease 29.6 TP53 MIR532 MIR31 MIR21 MIR20A MIR192
28 rectum cancer 29.5 TP53 MUTYH MLH1 MIR31 MIR21 MIR20A
29 hepatocellular carcinoma 29.4 TP53 MLH1 MIR532 MIR31 MIR21 MIR20A
30 large intestine adenoma 11.1
31 cecal benign neoplasm 11.1
32 large bowel leiomyoma 11.1
33 large intestine lipoma 11.1
34 cystadenocarcinoma 10.5 TP53 MIR21 KRAS
35 ampulla of vater benign neoplasm 10.5 KRAS HRAS APC
36 periampullary adenoma 10.5 MUTYH HRAS APC
37 trachea carcinoma in situ 10.5 KRAS HRAS
38 vaginal carcinosarcoma 10.5 TP53 KRAS HRAS
39 dermatopathia pigmentosa reticularis 10.5 MIR31 KRAS HRAS
40 pancreatoblastoma 10.5 KRAS HRAS CTNNB1
41 gastrointestinal adenoma 10.5 MUTYH MLH1 APC
42 cholangiocarcinoma 10.5 TP53 MIR21 KRAS CTNNB1
43 descending colon cancer 10.5 MLH1 KRAS HRAS
44 duodenal benign neoplasm 10.5 HRAS APC
45 liver angiosarcoma 10.5 TP53 KRAS HRAS
46 feingold syndrome 1 10.5 MIR20A MIR18A MIR17
47 sigmoid neoplasm 10.5 MLH1 KRAS HRAS
48 cystadenofibroma 10.5 TP53 KRAS HRAS
49 endosalpingiosis 10.5 TP53 KRAS HRAS
50 appendix adenocarcinoma 10.5 TP53 KRAS HRAS

Graphical network of the top 20 diseases related to Intestinal Benign Neoplasm:



Diseases related to Intestinal Benign Neoplasm

Symptoms & Phenotypes for Intestinal Benign Neoplasm

UMLS symptoms related to Intestinal Benign Neoplasm:


constipation; diarrhea

MGI Mouse Phenotypes related to Intestinal Benign Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.28 APC CTNNB1 HRAS KRAS MIR139 MIR31

Drugs & Therapeutics for Intestinal Benign Neoplasm

Drugs for Intestinal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bisacodyl Approved Phase 4 603-50-9 2391
2
Lutetium Lu 177 dotatate Approved, Investigational Phase 4 437608-50-9 76966897
3
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
4
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
5 Cathartics Phase 4
6 Laxatives Phase 4
7 Pharmaceutical Solutions Phase 4
8
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
9
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
10 Orange Approved Phase 3
11
Clavulanic acid Approved, Vet_approved Phase 3 58001-44-8 5280980
12
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
13
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
14
Ondansetron Approved, Withdrawn Phase 3 99614-02-5 4595
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Ofloxacin Approved Phase 3 82419-36-1 4583
17
Simvastatin Approved Phase 3 79902-63-9 54454
18
Morphine Approved, Investigational Phase 3 57-27-2 5288826
19
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
20
Lanreotide Approved Phase 3 108736-35-2 71349 6918011
21 Amoxicillin-Potassium Clavulanate Combination Phase 3
22 beta-Lactamase Inhibitors Phase 3
23 topoisomerase I inhibitors Phase 3
24 Anti-Bacterial Agents Phase 3
25 Anti-Infective Agents Phase 3
26 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
27 Calcium, Dietary Phase 3
28 Cytochrome P-450 Enzyme Inhibitors Phase 3
29 Antipsychotic Agents Phase 3
30 Anti-Anxiety Agents Phase 3
31 Neurotransmitter Agents Phase 3
32 Psychotropic Drugs Phase 3
33
Epoetin Alfa Phase 3
34 Hematinics Phase 3
35 Hypolipidemic Agents Phase 3
36 Anticholesteremic Agents Phase 3
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
38 Lipid Regulating Agents Phase 3
39 Excitatory Amino Acid Antagonists Phase 3
40 Respiratory System Agents Phase 3
41 Antitussive Agents Phase 3
42 Analgesics, Opioid Phase 3
43 Narcotics Phase 3
44
Calcium Nutraceutical Phase 3 7440-70-2 271
45
Carmustine Approved, Investigational Phase 2 154-93-8 2578
46
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
47
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
48
Melphalan Approved Phase 2 148-82-3 4053 460612
49
Etoposide Approved Phase 2 33419-42-0 36462
50
Epirubicin Approved Phase 2 56420-45-2 41867

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial. Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
2 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
3 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
4 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
5 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);Capecitabine
6 Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study. Completed NCT02608203 Phase 2, Phase 3 [68Ga]-DOTANOC PET/CT
7 Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer Completed NCT03350490 Phase 2, Phase 3 Life information rehabilitation therapy
8 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
9 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
10 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
11 Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery Completed NCT00994903 Phase 3 Simvastatin;Placebo
12 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
14 A Phase 3, Single-arm, Open-label, Multicentre Study to Assess the Efficacy and Safety of Deep Subcutaneous Injections of Lanreotide Autogel® 120 mg Administered Every 28 Days in Chinese Participants With Unresectable, Locally Advanced or Metastatic Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Active, not recruiting NCT04852679 Phase 3 Lanreotide autogel
15 Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
16 Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks? Unknown status NCT01037049 Phase 2
17 Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery Unknown status NCT02202928 Phase 2 Chemotherapy
18 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
19 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
20 Phase II Trial of Etoposide Plus Cisplatin Compared With Irinotecan Plus Cisplatin for First-line Treatment of Non-primary Pancreatic Metastatic and/or Unresectable Gastrointestinal Neuroendocrine Tumor G3 Type Unknown status NCT03963193 Phase 2 Etoposide;Irinotecan
21 A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 Unknown status NCT03457844 Phase 2 Anlotinib
22 An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy Completed NCT04080843 Phase 2 Anlotinib Hydrochloride;Capecitabine;Oxaliplatin
23 Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Completed NCT03043664 Phase 1, Phase 2 Lanreotide;Pembrolizumab
24 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
25 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
26 A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas Completed NCT00416351 Phase 1, Phase 2 clofarabine
27 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
28 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
29 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
30 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
31 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
32 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
33 Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
34 Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer Completed NCT01016639 Phase 1, Phase 2
35 Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
36 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
37 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
38 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
39 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
40 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
41 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
42 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
43 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
44 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
45 NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial Recruiting NCT03280407 Phase 2 Capecitabine;FOLFOX regimen (oxaliplatin/leucovorin/5FU);CAPOX (oxaliplatin/capecitabine)
46 Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial Recruiting NCT03271255 Phase 2 Apatinib Mesylate Tablets;Bevacizumab Injection
47 A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Recruiting NCT03891784 Phase 2 Abemaciclib
48 Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes Recruiting NCT04907643 Phase 2
49 A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation Recruiting NCT05194995 Phase 1, Phase 2 JAB-21822;Cetuximab
50 A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE) Recruiting NCT05332002 Phase 2 Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)

Search NIH Clinical Center for Intestinal Benign Neoplasm

Cochrane evidence based reviews: intestinal neoplasms

Genetic Tests for Intestinal Benign Neoplasm

Anatomical Context for Intestinal Benign Neoplasm

Organs/tissues related to Intestinal Benign Neoplasm:

FMA: Intestine
MalaCards : Small Intestine, Colon, Liver, Lung, Pancreas, Monocytes, Thyroid

Publications for Intestinal Benign Neoplasm

Articles related to Intestinal Benign Neoplasm:

(show top 50) (show all 1100)
# Title Authors PMID Year
1
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. 53 62
12460911 2002
2
Myosin Vb as a tumor suppressor gene in intestinal cancer. 62
36316444 2022
3
Huang Qin Decoction inhibits the initiation of experimental colitis associated carcinogenesis by controlling the PAD4 dependent NETs. 62
36155218 2022
4
Meat Intake, Cooking Methods, Doneness Preferences and Risk of Gastric Adenocarcinoma in the MCC-Spain Study. 62
36432538 2022
5
Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial. 62
36103060 2022
6
Polygenic early-onset colorectal cancer in pediatric patients. 62
35670754 2022
7
Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases. 62
36113229 2022
8
[Shenbai Jiedu Fang inhibits AOM/DSS-induced colorectal adenoma formation and carcinogenesis in mice via miRNA-22-mediated regulation of the PTEN/PI3K/AKT signaling pathway]. 62
36329578 2022
9
Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors. 62
36297407 2022
10
TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial-Mesenchymal Transition and Invasiveness. 62
36077674 2022
11
Life-threatening gastrointestinal bleeding caused by jejunal heterotopic gastric mucosa in an adult dog: a rare case report. 62
35974373 2022
12
Blocking DCIR mitigates colitis and prevents colorectal tumors by enhancing the GM-CSF-STAT5 pathway. 62
35926458 2022
13
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia. 62
35931031 2022
14
Multifocal organoids reveal clonal associations between synchronous intestinal tumors with pervasive heterogeneous drug responses. 62
35853873 2022
15
Celiac disease and the surgeon. 62
35221098 2022
16
The role of short-chain fatty acids in Clostridioides difficile infection: A review. 62
35545183 2022
17
Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. 62
35274815 2022
18
MicroRNA Profile of Human Small Intestinal Tumors Compared to Colorectal Tumors. 62
35566730 2022
19
Occult colon cancer with sepsis as the primary manifestation identified by bone marrow puncture: A case report. 62
35434087 2022
20
Imaging PPG for In Vivo Human Tissue Perfusion Assessment during Surgery. 62
35448221 2022
21
Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer. 62
35101901 2022
22
Mapping of novel loci involved in lung and colon tumor susceptibility by the use of genetically selected mouse strains. 62
34966170 2022
23
The effects of aerobic exercise on the intestinal tumors and flora of the ApcMin/+ mouse. 62
34436759 2022
24
Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy. 62
34245130 2022
25
Surgery for Cronkhite-Canada syndrome complicated with intussusception: A case report and review of literature. 62
35317544 2022
26
Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota. 62
35215376 2022
27
Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency. 62
34664536 2022
28
Qingchang Wenzhong Decoction Prevents the Occurrence of Intestinal Tumors by Regulating Intestinal Microbiota and Gasdermin E. 62
35910578 2022
29
Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apcmin/+ mouse model. 62
35693092 2022
30
Survival effects of primary and metastatic surgical treatment in metastatic small intestinal tumors: A propensity score-matching study. 62
35749551 2022
31
Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer. 62
35711841 2022
32
Akkermansia muciniphila administration exacerbated the development of colitis-associated colorectal cancer in mice. 62
34976176 2022
33
GPR43 Suppresses Intestinal Tumor Growth by Modification of the Mammalian Target of Rapamycin Complex 1 Activity in ApcMin/+ Mice. 62
34818236 2022
34
Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer. 62
35069904 2022
35
Involvement of parathyroid hormone-related peptide in the aggressive phenotype of colorectal cancer cells. 62
34887626 2021
36
PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. 62
34560002 2021
37
Long noncoding RNAs in intestinal homeostasis, regeneration, and cancer. 62
33899236 2021
38
Bridging the Species Gap: Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas. 62
34885050 2021
39
Brg1 is required to maintain colorectal cancer stem cells. 62
34415580 2021
40
Conditional CRISPR-Cas Genome Editing in Drosophila to Generate Intestinal Tumors. 62
34831379 2021
41
Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant. 62
34820467 2021
42
WNT2 activation through proximal germline deletion predisposes to small intestinal neuroendocrine tumors and intestinal adenocarcinomas. 62
34274970 2021
43
Endometriosis-associated intestinal tumors: a new challenge in clinical practice. 62
34423648 2021
44
Litopenaeus vannamei BMAL1 Is a Critical Mediator Regulating the Expression of Glucose Transporters and Can Be Suppressed by Constant Darkness. 62
34679914 2021
45
Tumors Induce Death in Nearby Cells to Gain Competitive Advantage. 62
34244214 2021
46
Anal Atresia in a Patient Who Had Undergone Hartmann Procedure. 62
34508065 2021
47
Association between intestinal neoplasms and celiac disease: A review. 62
34616509 2021
48
Gastrointestinal Stromal Tumor Associated with Neurofibromatosis Type 1 Simulating a Neurofibrosarcoma in a Black African Adult Patient. 62
34720831 2021
49
Microenvironmental innate immune signaling and cell mechanical responses promote tumor growth. 62
34197724 2021
50
The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. 62
33932349 2021

Variations for Intestinal Benign Neoplasm

Expression for Intestinal Benign Neoplasm

Search GEO for disease gene expression data for Intestinal Benign Neoplasm.

Pathways for Intestinal Benign Neoplasm

Pathways related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.47 TP53 MLH1 KRAS HRAS CTNNB1 APC
2
Show member pathways
12.31 TP53 KRAS HRAS CTNNB1
3
Show member pathways
12.28 TP53 KRAS HRAS CTNNB1
4
Show member pathways
12.23 APC CTNNB1 HRAS KRAS TP53
5 11.98 TP53 KRAS HRAS CTNNB1
6 11.87 TP53 MLH1 KRAS CTNNB1 APC
7 11.82 KRAS HRAS CTNNB1 APC
8 11.65 TP53 HRAS CTNNB1
9
Show member pathways
11.62 TP53 KRAS HRAS
10
Show member pathways
11.61 MIR20A MIR17 MIR143
11 11.56 TP53 KRAS HRAS CTNNB1 APC
12 11.54 HRAS CTNNB1 APC
13 11.49 TP53 KRAS HRAS CTNNB1
14 11.23 TP53 KRAS HRAS
15 10.99 TP53 MIR21 MIR20A MIR18A MIR17 MIR15A
16 10.7 KRAS HRAS CTNNB1 APC
17
Show member pathways
10.66 KRAS HRAS
18 10.27 TP53 MIR15A

GO Terms for Intestinal Benign Neoplasm

Cellular components related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A
2 RISC complex GO:0016442 9.6 MIR31 MIR21 MIR20A MIR192 MIR18A MIR17
3 extracellular vesicle GO:1903561 9.35 MIR21 MIR20A MIR192 MIR17 MIR15A

Biological processes related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.24 TP53 MIR21 MIR17 KRAS HRAS CTNNB1
2 negative regulation of cell population proliferation GO:0008285 10.22 TP53 MIR21 MIR15A HRAS CTNNB1 APC
3 positive regulation of apoptotic process GO:0043065 10.19 TP53 MIR21 MIR15A CTNNB1 APC
4 negative regulation of gene expression GO:0010629 9.97 TP53 MIR21 MIR20A MIR17 HRAS CTNNB1
5 negative regulation of angiogenesis GO:0016525 9.91 MIR21 MIR15A MIR143 CTNNB1
6 cellular response to gamma radiation GO:0071480 9.89 TP53 MIR21 HRAS
7 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.88 MIR17 MIR18A MIR20A TP53
8 negative regulation of inflammatory response GO:0050728 9.85 MIR142 MIR15A MIR20A MIR31
9 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.75 MIR21 MIR20A MIR17
10 negative regulation of sprouting angiogenesis GO:1903671 9.61 MIR20A MIR18A MIR17
11 miRNA-mediated gene silencing GO:0035195 9.6 MIR532 MIR31 MIR21 MIR20A MIR192 MIR18A
12 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.58 MIR21 MIR20A MIR143
13 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR20A MIR17
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.56 MIR21 MIR17
15 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.55 MIR15A MIR17 MIR20A MIR21 MIR31
16 positive regulation of metalloendopeptidase activity GO:1904685 9.54 MIR17 MIR21
17 negative regulation of vascular endothelial growth factor production GO:1904046 9.5 MIR20A MIR17 MIR15A
18 negative regulation of interleukin-21 production GO:0032705 9.46 MIR21 MIR192
19 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.43 MIR31 MIR20A MIR17
20 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.13 MIR20A MIR17 MIR143

Molecular functions related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 TP53 MIR31 MIR21 MIR20A MIR192 MIR17
2 mRNA base-pairing translational repressor activity GO:1903231 9.32 MIR31 MIR21 MIR20A MIR192 MIR18A MIR17

Sources for Intestinal Benign Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....